Reni‑cel gene‑editing trial discussed
Clinicians are evaluating the gene‑editing therapy reni‑cel for severe sickle‑cell disease in the phase 1/2 RUBY trial, with experts outlining trial assessment, enrollment and monitoring tasks. The trial discussion highlights the clinical‑research workflow around emerging gene therapies ((cgtlive.com)).
Sickle cell disease bends red blood cells into hard crescents that can block blood flow, trigger extreme pain, and damage organs. In the RUBY trial, doctors are testing renizgamglogene autogedtemcel, or reni-cel, a one-time gene-edited cell therapy meant to keep those cells rounder by raising fetal hemoglobin. (nejm.org) Reni-cel is made from a patient’s own blood-forming stem cells, which are collected, edited outside the body, and then infused back after high-dose busulfan chemotherapy clears space in the bone marrow. The edit uses CRISPR-Cas12a to change the HBG1 and HBG2 gene promoters so the body starts making more fetal hemoglobin again. (ashpublications.org) That matters in sickle cell disease because fetal hemoglobin is the form babies make before birth, and higher levels can stop hemoglobin from clumping into the rigid fibers that deform red cells. The reni-cel edits are designed to mimic hereditary persistence of fetal hemoglobin, a naturally occurring trait linked to milder disease. (ashpublications.org) At the American Society of Hematology meeting in Orlando in December 2025, Cleveland Clinic physician Rabi Hanna said the RUBY study had enrolled 40 patients ages 12 to 50, including 7 younger than 18. He said median follow-up was about 13.5 months, 4 patients had more than 2 years of follow-up, and 38 of 40 were pain-free. (cgtlive.com) The peer-reviewed data published in The New England Journal of Medicine on April 1, 2026 covered 28 treated patients from that larger program. Cleveland Clinic said 27 of 28 had no painful sickle cell crises after treatment, while mean total hemoglobin rose from 9.8 grams per deciliter before treatment to 13.8 grams per deciliter at 6 months. (newsroom.clevelandclinic.org) Editas Medicine reported the same 28-patient cutoff from October 29, 2024 as a median 9.5 months after infusion, with 11 patients followed for more than a year. The company said mean fetal hemoglobin reached 48.1% at month 6 and the share of fetal-hemoglobin-containing red cells stayed above 90% from month 4 through last follow-up. (ir.editasmedicine.com) The trial discussion now is not only about whether the edit works, but about the clinical workflow around it. Hanna told CGTLive that teams have to identify patients with a severe sickle cell phenotype, complete transplant-style assessments, manage stem-cell collection and busulfan conditioning, and monitor recovery after infusion. (cgtlive.com) Reni-cel is also entering a more crowded field than earlier sickle cell gene-therapy studies did. CGTLive noted that two gene therapies were already approved for sickle cell disease by December 2025: exagamglogene autotemcel, sold as Casgevy, and lovotibeglogene autotemcel, sold as Lyfgenia. (cgtlive.com) The main safety tradeoff has not been the edit itself so far, but the transplant process around it. Investigators said the safety profile in RUBY was consistent with myeloablative busulfan conditioning and autologous stem-cell transplant, and Hanna said there had been no deaths in the 40 enrolled patients he discussed at the 2025 meeting. (ir.editasmedicine.com, cgtlive.com) What comes next is more follow-up, not a quick verdict. The RUBY trial is still ongoing, and the case for reni-cel will rest on whether the pain relief, higher hemoglobin, and fetal-hemoglobin gains hold up as more patients move past the first year and beyond. (ashpublications.org, cgtlive.com)
